Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Second Generation Oral Ganaxolone by Marinus Pharmaceuticals for Lennox-Gastaut Syndrome: Likelihood of Approval
Second Generation Oral Ganaxolone is under clinical development by Marinus Pharmaceuticals and currently in Phase II for Lennox-Gastaut Syndrome. According...